





PHARMACEUTICAL 2021

GALECTIN THERAPEUTICS INC Rank 194 of 402



The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 56% points above the market average of 47%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 29,465 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 5,399 |
| Liabilities, Non-Current | 8.0 |
| Other Assets | 135 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | -21 |
| Other Revenues | 0 |
| Property and Equipment | 0 |
| Research and Development | 17,976 |
| Selling, General and Administrative Expense | 5,468 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 29,600 |
| Liabilities | 5,407 |
| Expenses | 23,444 |
| Revenues | 0 |
| Stockholders Equity | 24,193 |
| Net Income | -23,465 |
| Comprehensive Net Income | -23,465 |
| Economic Capital Ratio | 104% |